Overview of Dr. Rosen
Dr. Ezra Rosen is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from David Geffen School of Medicine at UCLA and has been in practice 9 years. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 20 publications and over 500 citings.
Office
300 East 66th Street
Floors 1 - 4
New York, NY 10065
Education & Training
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 2013 - 2016
David Geffen School of Medicine at UCLAClass of 2013
Certifications & Licensure
FL State Medical License 2022 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2016 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 343 citationsNTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfallsJames P. Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y. Rosen
Modern Pathology. 2020-01-01 - 24 citationsAvelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Ag...Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, Vivek Narayan, Kan Yonemori
JAMA Oncology. 2023-01-01 - 9 citationsGenomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.Diana Mandelker, Antonio Marra, Binbin Zheng-Lin, Pier Selenica, Juan Blanco-Heredia
Journal of Clinical Oncology. 2023-11-20
Press Mentions
eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual MeetingApril 26th, 2023- SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating MutationsAugust 3rd, 2021
- Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast CancerOctober 20th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
